The biological basis of severe outcomes in Anaplasma phagocytophilum infection

FEMS Immunology and Medical Microbiology

Volumn 64, Issue 1, 2012, Pages 13-20

  Dumler, J Stephen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplasma; Cytotoxic lymphocyte; Hemophagocytic syndrome; Immunopathology; Macrophage activation syndrome; Rickettsia

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; STAT PROTEIN;

APOPTOSIS; CD8+ T LYMPHOCYTE; CELL MIGRATION; CYTOTOXIC LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; DNA DEGRADATION; EX VIVO STUDY; FATALITY; GENE MUTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION CONTROL; INFLAMMATION; INTENSIVE CARE; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

ANAPLASMA PHAGOCYTOPHILUM; ANIMALS; DISEASE MODELS, ANIMAL; EHRLICHIOSIS; HUMANS; IMMUNITY, INNATE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84855661517     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00909.x     Document Type: Short Survey

References (71)

1. Akkoyunlu M & Fikrig E (2000) Gamma interferon dominates the murine cytokine response to the agent of human granulocytic ehrlichiosis and helps to control the degree of early rickettsemia. Infect Immun 68: 1827-1833.
2. Akkoyunlu M, Malawista SE, Anguita J & Fikrig E (2001) Exploitation of interleukin-8-induced neutrophil chemotaxis by the agent of human granulocytic ehrlichiosis. Infect Immun 69: 5577-5588.
3. Arceci RJ (2008) When T cells and macrophages do not talk: the hemophagocytic syndromes. Curr Opin Hematol 15: 359-367.
4. Bakken JS & Dumler JS (2000) Human granulocytic ehrlichiosis. Clin Infect Dis 31: 554-560.
5. Bakken JS & Dumler JS (2006) Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. Ann NY Acad Sci 1078: 236-247.
6. Bakken JS & Dumler S (2008) Human granulocytic anaplasmosis. Infect Dis Clin North Am 22: 433-448, viii.
7. Bakken JS, Dumler JS, Chen SM, Eckman MR, Van Etta LL & Walker DH (1994) Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA 272: 212-218.
8. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K & Dumler JS (1996) Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 275: 199-205.
9. Bakken JS, Goellner P, Van Etten M et al. (1998) Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis 27: 1491-1496.
10. Bakken JS, Aguero-Rosenfeld ME, Tilden RL et al. (2001) Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 32: 862-870.
11. Bakken JS, Haller I, Riddell D, Walls JJ & Dumler JS (2002) The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 34: 22-27.
12. Banerjee R, Anguita J & Fikrig E (2000a) Granulocytic ehrlichiosis in mice deficient in phagocyte oxidase or inducible nitric oxide synthase. Infect Immun 68: 4361-4362.
13. Banerjee R, Anguita J, Roos D & Fikrig E (2000b) Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J Immunol 164: 3946-3949.
14. Behrens EM, Beukelman T, Paessler M & Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34: 1133-1138.
15. Browning MD, Garyu JW, Dumler JS & Scorpio DG (2006) Role of reactive nitrogen species in development of hepatic injury in a C57BL/6 mouse model of human granulocytic anaplasmosis. Comp Med 56: 55-62.
16. Bunnell JE, Trigiani ER, Srinivas SR & Dumler JS (1999) Development and distribution of pathologic lesions are related to immune status and tissue deposition of human granulocytic ehrlichiosis agent-infected cells in a murine model system. J Infect Dis 180: 546-550.
17. Carlyon JA & Fikrig E (2006) Mechanisms of evasion of neutrophil killing by Anaplasma phagocytophilum. Curr Opin Hematol 13: 28-33.
18. Carlyon JA, Chan WT, Galan J, Roos D & Fikrig E (2002) Repression of rac2 mRNA expression by Anaplasma phagocytophila is essential to the inhibition of superoxide production and bacterial proliferation. J Immunol 169: 7009-7018.
19. Carlyon JA, Abdel-Latif D, Pypaert M, Lacy P & Fikrig E (2004) Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection. Infect Immun 72: 4772-4783.
20. Chapman AS, Bakken JS, Folk SM et al. (2006) Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 55: 1-27.
21. Choi KS & Dumler JS (2003) Early induction and late abrogation of respiratory burst in A. phagocytophilum-infected neutrophils. Ann N Y Acad Sci 990: 488-493.
22. Choi KS & Dumler JS (2007) Mitogenic component in polar lipid-enriched Anaplasma phagocytophilum membranes. Clin Vaccine Immunol 14: 1260-1265.
23. Choi KS, Scorpio DG, Barat NC & Dumler JS (2007a) Msp2 variation in Anaplasma phagocytophilum in vivo does not stimulate T cell immune responses or interferon-gamma production. FEMS Immunol Med Microbiol 49: 374-386.
24. Choi KS, Webb T, Oelke M, Scorpio DG & Dumler JS (2007b) Differential innate immune cell activation and proinflammatory response in Anaplasma phagocytophilum infection. Infect Immun 75: 3124-3130.
25. Crowe NY, Uldrich AP, Kyparissoudis K et al. (2003) Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 171: 4020-4027.
26. Davies RS, Madigan JE, Hodzic E, Borjesson DL & Dumler JS (2011) Dexamethasone-induced cytokine changes associated with diminished disease severity in horses infected with Anaplasma phagocytophilum. Clin Vaccine Immunol 18: 1962-1968.
27. Davis DM & Dustin ML (2004) What is the importance of the immunological synapse? Trends Immunol 25: 323-327.
28. Dumler JS, Trigiani ER, Bakken JS, Aguero-Rosenfeld ME & Wormser GP (2000) Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol 7: 6-8.
29. Dumler JS, Choi KS, Garcia-Garcia JC et al. (2005) Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 11: 1828-1834.
30. Dumler JS, Barat NC, Barat CE & Bakken JS (2007a) Human granulocytic anaplasmosis and macrophage activation. Clin Infect Dis 45: 199-204.
31. Dumler JS, Madigan JE, Pusterla N & Bakken JS (2007b) Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 45(Suppl 1): S45-S51.
32. Fisman DN (2000) Hemophagocytic syndromes and infection. Emerg Infect Dis 6: 601-608.
33. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V & Gastinne H (1997) Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 103: 114-120.
34. Garcia-Garcia JC, Barat NC, Trembley SJ & Dumler JS (2009a) Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum. PLoS Pathog 5: e1000488.
35. Garcia-Garcia JC, Rennoll-Bankert KE, Pelly S, Milstone AM & Dumler JS (2009b) Silencing of host cell CYBB gene expression by the nuclear effector AnkA of the intracellular pathogen Anaplasma phagocytophilum. Infect Immun 77: 2385-2391.
36. Godfrey DI & Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114: 1379-1388.
37. Grom AA (2004) Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 50: 689-698.
38. Hodzic E, Ijdo JW, Feng S et al. (1998) Granulocytic ehrlichiosis in the laboratory mouse. J Infect Dis 177: 737-745.
39. Ijdo JW & Mueller AC (2004) Neutrophil NADPH oxidase is reduced at the Anaplasma phagocytophilum phagosome. Infect Immun 72: 5392-5401.
40. Ijdo JW, Meek JI, Cartter ML et al. (2000) The emergence of another tickborne infection in the 12-town area around Lyme, Connecticut: human granulocytic ehrlichiosis. J Infect Dis 181: 1388-1393.
41. Ismail N, Olano JP, Feng HM & Walker DH (2002) Current status of immune mechanisms of killing of intracellular microorganisms. FEMS Microbiol Lett 207: 111-120.
42. Jahangir A, Kolbert C, Edwards W, Mitchell P, Dumler JS & Persing DH (1998) Fatal pancarditis associated with human granulocytic Ehrlichiosis in a 44-year-old man. Clin Infect Dis 27: 1424-1427.
43. Janka G & zur Stadt U (2005) Familial and acquired hemophagocytic lymphohistiocytosis. Hematology 2005: 82-88.
44. Kim HY & Rikihisa Y (2000) Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44. Infect Immun 68: 3394-3402.
45. Klein MB, Hu S, Chao CC & Goodman JL (2000) The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. J Infect Dis 182: 200-205.
46. Kronenberg M (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
47. Lang R (2005) Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 210: 63-76.
48. Larroche C & Mouthon L (2004) Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 3: 69-75.
49. Lepidi H, Bunnell JE, Martin ME, Madigan JE, Stuen S & Dumler JS (2000) Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg 62: 29-37.
50. Lin M, den Dulk-Ras A, Hooykaas PJ & Rikihisa Y (2007) Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. Cell Microbiol 9: 2644-2657.
51. von Loewenich FD, Scorpio DG, Reischl U, Dumler JS & Bogdan C (2004) Frontline: control of Anaplasma phagocytophilum, an obligate intracellular pathogen, in the absence of inducible nitric oxide synthase, phagocyte NADPH oxidase, tumor necrosis factor, Toll-like receptor (TLR)2 and TLR4, or the TLR adaptor molecule MyD88. Eur J Immunol 34: 1789-1797.
52. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A & Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
53. Martin ME, Bunnell JE & Dumler JS (2000) Pathology, immunohistology, and cytokine responses in early phases of human granulocytic ehrlichiosis in a murine model. J Infect Dis 181: 374-378.
54. Martin ME, Caspersen K & Dumler JS (2001) Immunopathology and ehrlichial propagation are regulated by interferon-gamma and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol 158: 1881-1888.
55. Mattner J, Debord KL, Ismail N et al. (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
56. Menasche G, Feldmann J, Fischer A & de Saint Basile G (2005) Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev 203: 165-179.
57. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73: 209-212.
58. Pedra JH, Mattner J, Tao J et al. (2008) c-Jun NH2-terminal kinase 2 inhibits gamma interferon production during Anaplasma phagocytophilum infection. Infect Immun 76: 308-316.
59. Ravelli A, Magni-Manzoni S, Pistorio A et al. (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146: 598-604.
60. Rikihisa Y (2011) Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum. Clin Microbiol Rev 24: 469-489.
61. Scharton TM & Scott P (1993) Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 178: 567-577.
62. Scorpio DG, Akkoyunlu M, Fikrig E & Dumler JS (2004) CXCR2 blockade influences Anaplasma phagocytophilum propagation but not histopathology in the mouse model of human granulocytic anaplasmosis. Clin Diagn Lab Immunol 11: 963-968.
63. Scorpio DG, von Loewenich FD, Gobel H, Bogdan C & Dumler JS (2006) Innate immune response to Anaplasma phagocytophilum contributes to hepatic injury. Clin Vaccine Immunol 13: 806-809.
64. Scorpio DG, Leutenegger C, Berger J, Barat N, Madigan JE & Dumler JS (2008) Sequential analysis of Anaplasma phagocytophilum msp2 transcription in murine and equine models of human granulocytic anaplasmosis. Clin Vaccine Immunol 15: 418-424.
65. Thomas V & Fikrig E (2007) Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection. Cell Microbiol 9: 1730-1737.
66. Voskoboinik I, Smyth MJ & Trapani JA (2006) Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6: 940-952.
67. Walker DH & Dumler JS (1995) Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Infect Agents Dis 4: 167-170.
68. Walker DH & Dumler JS (1996) Emergence of the ehrlichioses as human health problems. Emerg Infect Dis 2: 18-29.
69. Wormser GP, Dattwyler RJ, Shapiro ED et al. (2006) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43: 1089-1134.
70. Zhang L, Shan A, Mathew B et al. (2008a) Rickettsial Seroepidemiology among farm workers, Tianjin, People's Republic of China. Emerg Infect Dis 14: 938-940.
71. Zhang L, Liu Y, Ni D et al. (2008b) Nosocomial transmission of human granulocytic anaplasmosis in China. JAMA 300: 2263-2270.